Report cover image

Global Opioids Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 197 Pages
SKU # APRC20280453

Description

Summary

According to APO Research, the global Opioids Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Opioids Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Opioids Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Opioids Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Opioids Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Opioids Drug market include Teva, Mylan, Pfizer, Purdue Pharma, Mallinckrodt, J&J, INSYS, Hikma and Endo, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Opioids Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Opioids Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Opioids Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Opioids Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Opioids Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Opioids Drug sales, projected growth trends, production technology, application and end-user industry.

Opioids Drug Segment by Company

Teva
Mylan
Pfizer
Purdue Pharma
Mallinckrodt
J&J
INSYS
Hikma
Endo
Egalet
Collegium
Amneal Pharma
Opioids Drug Segment by Type

Fentanyl
Codeine
Oxycodone
Hydromorphone
Opioids Drug Segment by Application

Pain Relief
Anesthesia
Others
Opioids Drug Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Opioids Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Opioids Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Opioids Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Opioids Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioids Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioids Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioids Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioids Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioids Drug industry.
Chapter 3: Detailed analysis of Opioids Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Opioids Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Opioids Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Opioids Drug Sales Value (2020-2031)
1.2.2 Global Opioids Drug Sales Volume (2020-2031)
1.2.3 Global Opioids Drug Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Opioids Drug Market Dynamics
2.1 Opioids Drug Industry Trends
2.2 Opioids Drug Industry Drivers
2.3 Opioids Drug Industry Opportunities and Challenges
2.4 Opioids Drug Industry Restraints
3 Opioids Drug Market by Company
3.1 Global Opioids Drug Company Revenue Ranking in 2024
3.2 Global Opioids Drug Revenue by Company (2020-2025)
3.3 Global Opioids Drug Sales Volume by Company (2020-2025)
3.4 Global Opioids Drug Average Price by Company (2020-2025)
3.5 Global Opioids Drug Company Ranking (2023-2025)
3.6 Global Opioids Drug Company Manufacturing Base and Headquarters
3.7 Global Opioids Drug Company Product Type and Application
3.8 Global Opioids Drug Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Opioids Drug Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Opioids Drug Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Opioids Drug Market by Type
4.1 Opioids Drug Type Introduction
4.1.1 Fentanyl
4.1.2 Codeine
4.1.3 Oxycodone
4.1.4 Hydromorphone
4.2 Global Opioids Drug Sales Volume by Type
4.2.1 Global Opioids Drug Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Opioids Drug Sales Volume by Type (2020-2031)
4.2.3 Global Opioids Drug Sales Volume Share by Type (2020-2031)
4.3 Global Opioids Drug Sales Value by Type
4.3.1 Global Opioids Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Opioids Drug Sales Value by Type (2020-2031)
4.3.3 Global Opioids Drug Sales Value Share by Type (2020-2031)
5 Opioids Drug Market by Application
5.1 Opioids Drug Application Introduction
5.1.1 Pain Relief
5.1.2 Anesthesia
5.1.3 Others
5.2 Global Opioids Drug Sales Volume by Application
5.2.1 Global Opioids Drug Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Opioids Drug Sales Volume by Application (2020-2031)
5.2.3 Global Opioids Drug Sales Volume Share by Application (2020-2031)
5.3 Global Opioids Drug Sales Value by Application
5.3.1 Global Opioids Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Opioids Drug Sales Value by Application (2020-2031)
5.3.3 Global Opioids Drug Sales Value Share by Application (2020-2031)
6 Opioids Drug Regional Sales and Value Analysis
6.1 Global Opioids Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Opioids Drug Sales by Region (2020-2031)
6.2.1 Global Opioids Drug Sales by Region: 2020-2025
6.2.2 Global Opioids Drug Sales by Region (2026-2031)
6.3 Global Opioids Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Opioids Drug Sales Value by Region (2020-2031)
6.4.1 Global Opioids Drug Sales Value by Region: 2020-2025
6.4.2 Global Opioids Drug Sales Value by Region (2026-2031)
6.5 Global Opioids Drug Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Opioids Drug Sales Value (2020-2031)
6.6.2 North America Opioids Drug Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Opioids Drug Sales Value (2020-2031)
6.7.2 Europe Opioids Drug Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Opioids Drug Sales Value (2020-2031)
6.8.2 Asia-Pacific Opioids Drug Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Opioids Drug Sales Value (2020-2031)
6.9.2 South America Opioids Drug Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Opioids Drug Sales Value (2020-2031)
6.10.2 Middle East & Africa Opioids Drug Sales Value Share by Country, 2024 VS 2031
7 Opioids Drug Country-level Sales and Value Analysis
7.1 Global Opioids Drug Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Opioids Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Opioids Drug Sales by Country (2020-2031)
7.3.1 Global Opioids Drug Sales by Country (2020-2025)
7.3.2 Global Opioids Drug Sales by Country (2026-2031)
7.4 Global Opioids Drug Sales Value by Country (2020-2031)
7.4.1 Global Opioids Drug Sales Value by Country (2020-2025)
7.4.2 Global Opioids Drug Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Opioids Drug Sales Value Growth Rate (2020-2031)
7.5.2 USA Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Opioids Drug Sales Value Growth Rate (2020-2031)
7.6.2 Canada Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Opioids Drug Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Opioids Drug Sales Value Growth Rate (2020-2031)
7.8.2 Germany Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Opioids Drug Sales Value Growth Rate (2020-2031)
7.9.2 France Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 France Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Opioids Drug Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Opioids Drug Sales Value Growth Rate (2020-2031)
7.11.2 Italy Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Opioids Drug Sales Value Growth Rate (2020-2031)
7.12.2 Spain Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Opioids Drug Sales Value Growth Rate (2020-2031)
7.13.2 Russia Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Opioids Drug Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Opioids Drug Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Opioids Drug Sales Value Growth Rate (2020-2031)
7.16.2 China Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 China Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Opioids Drug Sales Value Growth Rate (2020-2031)
7.17.2 Japan Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Opioids Drug Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Opioids Drug Sales Value Growth Rate (2020-2031)
7.19.2 India Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 India Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Opioids Drug Sales Value Growth Rate (2020-2031)
7.20.2 Australia Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Opioids Drug Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Opioids Drug Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Opioids Drug Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Opioids Drug Sales Value Growth Rate (2020-2031)
7.24.2 Chile Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Opioids Drug Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Opioids Drug Sales Value Growth Rate (2020-2031)
7.26.2 Peru Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Opioids Drug Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Opioids Drug Sales Value Growth Rate (2020-2031)
7.28.2 Israel Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Opioids Drug Sales Value Growth Rate (2020-2031)
7.29.2 UAE Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Opioids Drug Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Opioids Drug Sales Value Growth Rate (2020-2031)
7.31.2 Iran Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Opioids Drug Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Opioids Drug Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Opioids Drug Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Opioids Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Teva
8.1.1 Teva Comapny Information
8.1.2 Teva Business Overview
8.1.3 Teva Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.1.4 Teva Opioids Drug Product Portfolio
8.1.5 Teva Recent Developments
8.2 Mylan
8.2.1 Mylan Comapny Information
8.2.2 Mylan Business Overview
8.2.3 Mylan Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.2.4 Mylan Opioids Drug Product Portfolio
8.2.5 Mylan Recent Developments
8.3 Pfizer
8.3.1 Pfizer Comapny Information
8.3.2 Pfizer Business Overview
8.3.3 Pfizer Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.3.4 Pfizer Opioids Drug Product Portfolio
8.3.5 Pfizer Recent Developments
8.4 Purdue Pharma
8.4.1 Purdue Pharma Comapny Information
8.4.2 Purdue Pharma Business Overview
8.4.3 Purdue Pharma Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.4.4 Purdue Pharma Opioids Drug Product Portfolio
8.4.5 Purdue Pharma Recent Developments
8.5 Mallinckrodt
8.5.1 Mallinckrodt Comapny Information
8.5.2 Mallinckrodt Business Overview
8.5.3 Mallinckrodt Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.5.4 Mallinckrodt Opioids Drug Product Portfolio
8.5.5 Mallinckrodt Recent Developments
8.6 J&J
8.6.1 J&J Comapny Information
8.6.2 J&J Business Overview
8.6.3 J&J Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.6.4 J&J Opioids Drug Product Portfolio
8.6.5 J&J Recent Developments
8.7 INSYS
8.7.1 INSYS Comapny Information
8.7.2 INSYS Business Overview
8.7.3 INSYS Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.7.4 INSYS Opioids Drug Product Portfolio
8.7.5 INSYS Recent Developments
8.8 Hikma
8.8.1 Hikma Comapny Information
8.8.2 Hikma Business Overview
8.8.3 Hikma Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.8.4 Hikma Opioids Drug Product Portfolio
8.8.5 Hikma Recent Developments
8.9 Endo
8.9.1 Endo Comapny Information
8.9.2 Endo Business Overview
8.9.3 Endo Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.9.4 Endo Opioids Drug Product Portfolio
8.9.5 Endo Recent Developments
8.10 Egalet
8.10.1 Egalet Comapny Information
8.10.2 Egalet Business Overview
8.10.3 Egalet Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.10.4 Egalet Opioids Drug Product Portfolio
8.10.5 Egalet Recent Developments
8.11 Collegium
8.11.1 Collegium Comapny Information
8.11.2 Collegium Business Overview
8.11.3 Collegium Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.11.4 Collegium Opioids Drug Product Portfolio
8.11.5 Collegium Recent Developments
8.12 Amneal Pharma
8.12.1 Amneal Pharma Comapny Information
8.12.2 Amneal Pharma Business Overview
8.12.3 Amneal Pharma Opioids Drug Sales, Value and Gross Margin (2020-2025)
8.12.4 Amneal Pharma Opioids Drug Product Portfolio
8.12.5 Amneal Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Opioids Drug Value Chain Analysis
9.1.1 Opioids Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Opioids Drug Sales Mode & Process
9.2 Opioids Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Opioids Drug Distributors
9.2.3 Opioids Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.